Axsome Therapeutics is trading at $238.24 (4.3% down) as investors lock in gains following a significant rally driven by regulatory milestones and strong financial performance.
- The stock recently climbed after the FDA approved a label expansion for Auvelity to treat agitation associated with Alzheimer’s disease.
- Growth was further supported by robust Q1 2026 results, featuring revenue of $191.2 million, a 57% increase year-over-year.
- With no fresh news today and broader markets trading higher, the current move is attributed to profit-taking after the recent surge.